Using Critical Race Theory to Understand Trial Participation Among Black Individuals With Systemic Lupus Erythematosus: A Qualitative Study of Patients and Caregivers.


Journal

Arthritis care & research
ISSN: 2151-4658
Titre abrégé: Arthritis Care Res (Hoboken)
Pays: United States
ID NLM: 101518086

Informations de publication

Date de publication:
10 2021
Historique:
received: 27 08 2020
accepted: 22 04 2021
pubmed: 12 5 2021
medline: 16 11 2021
entrez: 11 5 2021
Statut: ppublish

Résumé

Black patients with systemic lupus erythematous (SLE) experience greater disease incidence and severity than White patients, and yet they are underrepresented in SLE clinical trials. We applied Critical Race Theory to qualitatively explore the influence of racism on the underrepresentation of Black patients in SLE clinical trials and to develop a framework for future intervention. We conducted focus group sessions in Chicago and Boston with Black adults (ages ≥18 years) with SLE and their caregivers. We queried the participants about their knowledge regarding clinical trials, factors that might motivate or hinder trial participation, and how race and experiences of racism might impact clinical trial participation. Focus group responses were transcribed verbatim and analyzed thematically. We held 4 focus groups (n = 31 participants); 20 participants had SLE, and 11 were caregivers. All participants were Black, 90% were women, and the mean age was 54 years. Qualitative analyses revealed several themes that negatively impact trial participation, including mistrust related to racism, concerns about assignment to placebo groups, strict study exclusion criteria, and SLE-related concerns. Factors that motivated trial participation included recommendations from physicians and reputable institutions, a desire to help the greater good, and culturally sensitive marketing of trials. Actions to improve clinical trial participation among Black individuals should focus on reframing how trial information is presented and disseminated and on reevaluating barriers that may restrict trial participation. Additionally, researchers must acknowledge and respond to the presence of racial bias in health care. Community-academic partnerships may help build trust and reduce fears of mistreatment among Black individuals with SLE.

Identifiants

pubmed: 33973413
doi: 10.1002/acr.24635
pmc: PMC8557360
mid: NIHMS1747298
doi:

Types de publication

Journal Article Multicenter Study Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1387-1395

Subventions

Organisme : NIMHD NIH HHS
ID : U54 MD011227
Pays : United States
Organisme : U.S. Department of Health and Human Services
ID : 1 CPIMP181168-01-00
Organisme : NIMHD NIH HHS
ID : L60 MD014430
Pays : United States
Organisme : NIAMS NIH HHS
ID : K24 AR002138
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG015281
Pays : United States

Informations de copyright

© 2021, American College of Rheumatology.

Références

J Transcult Nurs. 2016 Sep;27(5):456-63
pubmed: 25754929
Curr Rheumatol Rep. 2018 Mar 17;20(4):20
pubmed: 29550947
Soc Sci Med. 2010 Oct;71(8):1390-8
pubmed: 20822840
Arthritis Care Res (Hoboken). 2020 Oct;72(10):1481-1489
pubmed: 31350805
N Engl J Med. 2003 Mar 20;348(12):1170-5
pubmed: 12646676
Arthritis Rheumatol. 2014 Feb;66(2):369-78
pubmed: 24504809
Gerontologist. 2017 Apr 1;57(2):348-358
pubmed: 26553736
Lupus Sci Med. 2020 Mar 15;7(1):e000360
pubmed: 32201595
Lupus. 2019 Oct;28(12):1441-1451
pubmed: 31594456
Lupus Sci Med. 2018 Dec 11;5(1):e000297
pubmed: 30613420
J Health Care Poor Underserved. 2010 Aug;21(3):879-97
pubmed: 20693733
Q J Econ. 2018 Feb;133(1):407-455
pubmed: 30505005
MMWR Morb Mortal Wkly Rep. 2019 May 10;68(18):419-422
pubmed: 31071073
Lupus. 2015 Aug;24(9):918-26
pubmed: 25661509
J Allergy Clin Immunol. 2014 Jan;133(1):16-26
pubmed: 24369795
Patient Prefer Adherence. 2017 Jul 31;11:1295-1307
pubmed: 28814837
Arch Intern Med. 2002 Nov 25;162(21):2458-63
pubmed: 12437405
Arthritis Rheum. 1995 Sep;38(9):1260-70
pubmed: 7575721
Hastings Cent Rep. 1978 Dec;8(6):21-9
pubmed: 721302
Lupus. 2002;11(3):152-60
pubmed: 12004788
J Natl Med Assoc. 2005 Jul;97(7):951-6
pubmed: 16080664
J Gen Intern Med. 1999 Sep;14(9):537-46
pubmed: 10491242
Cancer. 2019 Nov 15;125(22):4096-4104
pubmed: 31355929

Auteurs

Rodlescia S Sneed (RS)

Michigan State University, East Lansing.

Maryann Mason (M)

Feinberg School of Medicine, Northwestern University, Chicago, Illinois.

Jessica N Williams (JN)

Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Corine Sinnette (C)

Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Kreager Taber (K)

Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Karen Mancera-Cuevas (K)

Illinois Department of Public Health, Springfield, and Feinberg School of Medicine, Northwestern University, Chicago, Illinois.

Gina Curry (G)

University of Chicago, Chicago, Illinois.

Patricia Canessa (P)

llinois Public Health Association, Springfield, Illinois.

Rosalind Ramsey-Goldman (R)

Feinberg School of Medicine, Northwestern University, Chicago, Illinois.

Candace H Feldman (CH)

Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH